...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Share Liquidity
1
Dec 17, 2017 12:06PM
2
Dec 17, 2017 02:37PM

Hi SanFran. Thanks. Yes I did see that and I am hoping someone will expand on it. I'd like to understand the pre IPO context. We new the PP was comming but his use of "pre IPO" makes me curious because Aureus does state it is phase 1.

Perhaps we'll hear more next week. My sense is that there is not enough science at this stage to provide any significant value. Although, this is cancer. Perhaps there will be early interest...perhaps to license testing.

Toinv

2
Dec 17, 2017 04:58PM
Share
New Message
Please login to post a reply